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Johansson ME, Andersson IJ, Alexanderson C, Skøtt O, Hol-
ma¨ng A, Bergstro¨m G. Hyperinsulinemic rats are normotensive
but sensitized to angiotensin II. Am J Physiol Regul Integr Comp
Physiol 294: R1240–R1247, 2008. First published January 23,
2008; doi:10.1152/ajpregu.00493.2007.—The effect of insulin on
blood pressure (BP) is debated, and an involvement of an activated
renin-angiotensin aldosterone system (RAAS) has been suggested.
We studied the effect of chronic insulin infusion on telemetry BP and
assessed sympathetic activity and dependence of the RAAS. Female
Sprague-Dawley rats received insulin (2 units/day, INS group, n 
12) or insulin combined with losartan (30 mg kg1 day1,
INSLOS group, n  10), the angiotensin II receptor antagonist, for
6 wk. Losartan-treated (LOS group, n  10) and untreated rats served
as controls (n  11). We used telemetry to measure BP and heart rate
(HR), and acute ganglion blockade and air-jet stress to investigate
possible control of BP by the sympathetic nervous system. In addition,
we used myograph technique to study vascular function ex vivo. The
INS and INSLOS groups developed euglycemic hyperinsulinemia.
Insulin did not affect BP but increased HR (27 beats/min on average).
Ganglion blockade reduced mean arterial pressure (MAP) similarly in
all groups. Air-jet stress did not increase sympathetic reactivity but
rather revealed possible blunting of the stress response in hyperinsu-
linemia. Chronic losartan markedly reduced 24-h-MAP in the
INSLOS group (38  1 mmHg P  0.001) compared with the
LOS group (18  1 mmHg, P  0.05). While insulin did not affect
vascular function per se, losartan improved endothelial function in the
aorta of insulin-treated rats. Our results raise doubt regarding the role
of hyperinsulinemia in hypertension. Moreover, we found no evidence
that insulin affects sympathetic nervous system activity. However,
chronic losartan treatment revealed an important interaction between
insulin and RAAS in BP control.
insulin/hyperinsulinemia; hypertension; air-jet stress
HYPERINSULINEMIA (or insulin resistance) often associates with
hypertension, and epidemiological studies have suggested a
positive correlation between hyperinsulinemia and hyperten-
sion, especially in obese subjects (28). An activated renin-
angiotensin aldosterone system (RAAS) might provide a mech-
anistic link between obesity, insulin, and hypertension. Indeed,
several studies have reported intricate cross talk between in-
sulin and RAAS; such cross talk is fairly well established
regarding deranged glucose metabolism. RAAS interventions
enhance insulin signaling, lower the risk of new onset of
diabetes in hypertensive subjects (23), and improve insulin
sensitivity in obese hypertensive subjects (9). However, other
studies suggest that cross talk occurs between insulin and
angiotensin II signaling in nonglucose-related actions of insu-
lin, e.g., mitogenic and growth-promoting effects (19) and also
in vasoregulation mediated by nitric oxide (NO) production
(36). Furthermore, activity in the sympathetic nervous system
is reportedly stimulated by RAAS activity, and both angioten-
sin II and insulin stimulate and/or facilitate sympathetic ner-
vous system (SNS) activity, thus forming another level of
interaction between these hormonal systems (26, 29, 31).
The literature on the hemodynamic effects of hyperinsuline-
mia in rats is vast. Most studies report increased blood pressure
(BP) following insulin infusion (5, 7, 26, 35); however, there are
also reports of no change in BP levels (22). Most of these studies
are well controlled with respect to insulin’s metabolic actions but
relatively short term (7–10 days). The more long-term studies
(10 days) are less well controlled regarding metabolic effects of
insulin and, importantly, have not used state-of-the-art tech-
nique to measure BP (7, 35). Thus, there is inconsistency
regarding the effect of insulin on BP in rats, and there is a
lack of more long-term studies using appropriate techniques
to measure BP.
We reported earlier that chronic insulin infusion increases
cardiac weight, an effect possibly mediated by angiotensin II
(32). Other reports suggest that an activated RAAS is involved
in the effect of insulin on BP showing that RAAS interventions
ameliorate insulin-mediated hypertension (5, 7, 30). We are
aware of no long-term studies that have addressed the issue of
insulin-RAAS interactions in hemodynamic control using
state-of-the-art techniques to measure BP.
Therefore, the aim of the current study was to use telem-
etry to measure carefully the true effect of RAAS interven-
tion and chronic insulin infusion on BP in freely moving
rats. We used a previously described model (13, 14) in
which insulin is infused by minipump, and glucose is
supplemented orally to counteract hypoglycemia. The model
enables us to study the long-term effects of hyperinsulin-
emia per se. We further examined whether insulin infusion
increases RAAS and SNS activity as well as cardiovascular
reactivity.
METHODS
Animals
Female Sprague-Dawley rats (B&K Universal, Sollentuna, Swe-
den) weighing 180 g were fed standard rat chow and tap water ad
libitum. Animals were housed at 21–25°C in a room with a 12:12-h
light-dark cycle. We acclimated animals to their surroundings for
1 wk before initiating the experiment. All animal procedures were
approved by the Animal Ethics Committee of Go¨teborg University.
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Experimental Protocol
Study 1. Chronic interactions between insulin and RAAS. We
treated the rats with insulin [2 units/day, Insuman Infusat (Apoteks-
bolaget), INS group, n  12] or insulin combined with losartan [30
mg kg1 day1, the ANG II receptor antagonist (Merck, Sharp and
Dohme, Sweden), INSLOS group, n  11] for 6 wk. Losartan-
treated (LOS group, n  10) and untreated rats (control group, n 
11) served as controls. To counteract hypoglycemia, rats were sup-
plemented with 10% glucose in drinking water throughout the study.
With this regimen, plasma glucose at 2 and 6 wk were not different
between groups (see data from 6 wk in Table 4). Blood samples were
drawn from conscious animals after 2 and 6 wk by cutting the tip of
the tail. To measure mean arterial pressure (MAP) and heart rate
(HR), we surgically implanted telemetry probes after 4 wk. Measure-
ments were performed at week 5. To determine whether SNS partic-
ipates in MAP control, we used acute ganglion blockade (20 mg/kg ip
hexamethonium chloride; Sigma, St. Louis, MO) and air-jet stress.
We killed all animals after 6 wk of treatment by overdosing them with
pentobarbital (0.015 ml/g body wt ip; Apoteksbolaget). After collect-
ing blood from the right ventricle, we carefully removed the aorta and
the mesenteric arteries, placed them in cold PSS buffer, and then used
a small vessel myograph to examine vascular function ex vivo.
Additionally, we carefully dissected the left and right ventricles and
mesenteric adipose tissue. The tissues were weighed, snap frozen in
liquid nitrogen, and stored at 80°C for further analysis.
Study 2. Acute interactions between insulin and RAAS. Study 2
explored the time course of BP and HR alterations. In addition, we
used acute selective antagonism to examine RAAS and SNS activity
during insulin treatment and used air-jet stress to activate SNS. After
fitting the rats with telemetry probes, we allowed 1-wk of recovery
before initiating insulin treatment. Insulin-treated rats were supple-
mented with 10% glucose in drinking water throughout the study. We
measured 24-h MAP and HR during 48 h, starting 3 days after insulin
treatment and then every second week throughout the entire treatment
period (6 wk). At weeks 2, 4, and 6, we administered acute dosing of
losartan (30 mg/kg ip) and two different ganglionic blockers (20
mg/kg hexamethonium and 10 mg/kg ip pentolinium tartrate; Acros
Organics, Geel, Belgium) as well as air-jet stress.
Drug Administration
Insulin was given as a continuous subcutaneous infusion using
osmotic pumps (Alzet, Scanbur, Sollentuna, Sweden). The groups
receiving insulin also received 10% glucose in their drinking water to
maintain euglycemia. Losartan was also administered in osmotic
pumps and implanted subcutaneously.
24-h BP Monitoring
To measure conscious 24-h BP, we used a telemetry technique
described previously (3). Briefly, we anesthetized rats with isoflurane,
implanted a radio telemetric transducer catheter (Data Science Inter-
national, St. Paul, MN) into the lower aorta 1 cm below the renal
arteries, and glued the catheter into position (3M Vetbond; 3M
Animal Care Products, St. Paul, MN). Following a recovery period
(1 wk), we placed the animals on a receiver plate and collected the
signal using Dataquest ART Version 3.1 (Data Science International).
We corrected the pressure signal for electronic offset, i.e., the average
of one measurement outside the animal before implantation and after
explantation. Offset values greater than 10 or 10 were excluded.
To analyze 24-h MAP, we averaged samples gathered on two subse-
quent days.
Stress Test and Acute Dosing
During stress exposure and drug testing, we sampled telemetry BP
using a short sampling duration and a high rate of repetition (5 s,
averaged each 10 s). We obtained stable and undisturbed baseline
values (10 min) at 8:00 AM, before entering the animal room. We
transferred the animals to a specially designed cage wherein a stream
of compressed air was blown for 10 min. MAP was then followed for
another 10-min recovery. To evaluate the involvement of SNS in BP
control, we administered acute intraperitoneal doses of ganglion
blockers hexamethonium or pentolinium, generating prompt and sta-
ble effects. We assessed the MAP response during a 5-min period
starting 4-min after dosing. To evaluate RAAS dependency on BP, we
administered a single dose of losartan (30 mg/kg ip). During week 2,
we noted a stable BP response 1 h after dosing; therefore, we used the
average BP value between 60–120 min and ceased sampling at 120
min. However, at weeks 4 and 6, BP response did not stabilize until
after 2 h, resulting in prolonged recording time. Therefore, we
calculated average BP 120–180 min after acute dosing.
The tests lasted 1 wk and were performed according to the follow-
ing schedule. Day 1, air-jet stress before noon and acute losartan in the
afternoon. Two days later, hexamethonium was administered before
noon followed by pentolinium in the afternoon, which allowed the
animals to recover for a minimum of 24 h between drug administra-
tion.
Ex Vivo Vascular Function
Using myograph technique described previously (4, 10, 11, 16, 17),
we examined ex vivo vascular function in the aortae and mesenteric
arteries. Briefly, we dissected aortic segments from the fifth intercos-
tal branch (midthoracic aorta). After equilibration, we preactivated the
vessel strips by adding KCl (100 mmol/l) and NE (105 mol/l
norepinephrine, Arterenol; Sigma). After subsequent equilibration, we
studied the NE concentration response relationship (109-105) in the
presence of propranolol (106 mol/l) to verify NE sensitivity. We
examined endothelium-dependent vasodilatory responses with ACh-
induced vasodilation (109-105 mol/l) following NE preconstriction
(75% of maximal constriction). Using sodium nitroprusside (105-
104 mol/l, SNP; Sigma), we evaluated endothelium-independent
relaxation. Finally, we performed ACh (109-105 mol/l) concentra-
tion response in the presence of NO synthase inhibitor N-nitro-
L-arginine (3 	 104 mol/l, L-NNA; Sigma).
After separating the second or third branch of the mesenteric artery
from adjacent connective tissue, we recorded isometric wall tension in
a MultiMyograph (model 610M; Danish Myo Technology, Aarhus,
Denmark). Following equilibration, the vessel segments were normal-
ized by stepwise extension according to the manufacturer’s protocol.
We activated the vessels with KCl and NE before initiating the
experiment. Following NE concentration response relationship (5.6	
107-3.2 	 105), we performed the endothelium-dependent relax-
ation response (1010-105 mol/l ACh), endothelium-independent
relaxation responses (1010-105 mol/l SNP), and NO-dependent
response (1010-105 mol/l ACh) in the presence of the NO synthase
inhibitor L-NNA (3 	 104 mol/l) as described above.
Quantification of Gene Expression
The protocol has been described previously (16). Briefly, we extracted
total mRNA with Trizol reagent (Life Technologies, Invitrogen, Paisley,
Scotland) followed by reverse transcription with Thermoscript RT-PCR
system (Invitrogen) according to the manufacturer’s protocol. We per-
formed relative quantification of mRNA expression on a LightCycler
(Roche Diagnostics, Mannheim, Germany) using SYBR Green I. We
designed PCR primers for 
1a-receptor using LightCycler Probe Design
Software version 1.0 (Roche Diagnostics). GAPDH served as an internal
control (11).
Immunoblotting
We performed protein extraction and Western blot analysis as
previously described (27, 33) with some minor modifications. Briefly,
mesenteric adipose tissues were homogenized on dry ice by using a
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mortar and pestle and then homogenization in PE buffer (10 mM
potassium phosphate buffer, pH 6.8 and 1 mM EDTA). After soni-
cation and centrifugation, we stored the supernatants at 70°C until
analysis. Protein concentrations were determined using the Bradford
assay. Protein (40 g) was loaded on 4–12% NuPAGE Bis-Tris gels
(Novex, Invitrogen) and electroblotted to a PVDF membrane (GE
Healthcare, Buckinghamshire, UK). We then incubated the mem-
branes with primary antibodies against AT1 receptor (sc-1173, diluted
1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA), ACE (sc-20791,
diluted 1:1,000; Santa Cruz), and -actin (A5441, diluted 1:1,000;
Sigma). Immunolabeling was visualized by chemiluminescence using
an alkaline-phosphatase-conjugated secondary antibody and CDP-
Star (Tropix; Applied Biosystems, Foster City, CA) as substrate.
Relative density of the bands was evaluated by densitometry using
Image Gauge software (version 3.45; Fuji Film). To correct for
loading differences, the density of each band was normalized to its
corresponding -actin band. Each gel/blot contained a positive control
(rat kidney). Mean densities of -actin-normalized bands are ex-
pressed as percentage of positive control for the respective gel.
Biochemical Analysis
Plasma renin concentrations (PRC) were measured by RIA of
angiotensin I, using the antibody-trapping technique (24). Only results
with linearity in serial dilutions (between 50- and 1,000-fold) were
accepted. Renin values, expressed in standard milliGoldblatt units per
milliliter (mGU/ml), were standardized with renin standards obtained
from the National Institutes for Biological Standards and Control
(Potters Bar, Herts. UK). We determined plasma glucose concentra-
tion with an autoanalyzer using the glucose oxidase method (YSI
Fig. 1. Effect of chronic angiotensin II type
1 receptor antagonist losartan on mean arte-
rial pressure (MAP; A), heart rate (HR; B)
and systolic blood pressure (C, top) and
diastolic blood pressure (C, bottom) in hy-
perinsulinemic (insulin group) and control
rats (n  6, control  losartan, n  10,
insulin, n  9, insulin  losartan, n  10).
Data were analyzed using ANOVA adapted
for repeated measurements. Data are ex-
pressed as means  SE.
Table 1. Effects of ganglion antagonist hexamethonium (20 mg/kg; Hexa) and air-jet stress on mean arterial pressure
(MAP) and heart rate (HR) in study 1, after 5 wk of treatment
Group n
Hexa MAP/HR Air-Jet Stress MAP/HR
Baseline Hexa Baseline Stress Poststress
Control 11 964/38015 683/37027 932/41925 1233/39722 1092/36925
Control losartan 10 937/41812 747/41717 835/42417 1125/39119 986/4437
Insulin 12 1053/40211 703/36713 1065/42514 1265/38915 1124/42217
Insulinlosartan 11 685/43216 456/38611 644/46114 834/43630 735/48110
Values are means  SE; n  number of rats per group.
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Scientific, Yellow Springs, OH). Commercial assay kits determined
the plasma levels of insulin (Linco Research, St. Charles, MO)
according to the manufacturer’s protocol.
Statistics
All data that fulfilled the criteria for parametric testing were
analyzed using one-way ANOVA (version 12.0.1; SPSS, Chicago, IL)
followed by Tukey’s honestly significant difference test. We evalu-
ated 24-h MAP and HR using repeated-measurements ANOVA
(STATISTICA 6 for Windows, version 7; StatSoft, Tulsa, OK)
followed by one-way ANOVA using group as factor, followed by
Bonferroni post hoc test. Because PRC data did not fulfill the criteria,
we examined such data using nonparametric statistics. The Kruskal-
Wallis test verified differences among means, and the Mann-Whitney
U-test assessed differences in individual groups. To evaluate time as
a factor, we also analyzed PRC data with repeated-measurements
ANOVA after logarithmic transformation. We used the Student’s
t-test to compare control and INS groups in study 2. All data are
expressed as means  SE. A value of P  0.05 was considered
statistically significant.
RESULTS
Study 1
Similar MAP but marked hypotensive effect of losartan.
Insulin did not affect MAP per se (Fig. 1, repeated-measure-
ments ANOVA; time, P  0.0001, group, P  0.0001
time*group, P  0.0095). Losartan decreased BP significantly
compared with control (18  1 mmHg, P  0.05). MAP
reduction was more marked in the INSLOS group (38  1
mmHg, P 0.01). Although there were numerical differences,
we observed no significant HR differences (repeated-measure-
ments ANOVA; time, P  0.0001, group, P  0.02,
time*group, P  0.721).
Sympathetic activity and air-jet stress. Hexamethonium re-
duced MAP similarly in all groups (control, 29  4; INS,
32 3; control-LOS,26 5; and INSLOS ,34 6%
Fig. 2. ACh-mediated vasodilation in aortae of control vs. insulin-treated rats
(A), control vs. control losartan-treated rats (B), and insulin vs. insulin
losartan-treated rats (C). Data are expressed as means  SE **P  0.01.
Fig. 3. Expression of AT1 receptor (A) and ACE proteins (B) in mesenteric
adipose tissue in hyperinsulinemic (insulin) and control rats with or without
losartan treatment. Top insets, one representative immunoblot (control, control
losartan, insulin, and insulin losartan, respectively). The density of each band
was normalized to its corresponding -actin band. Mean densities of -actin-
normalized bands are expressed as %positive control for the respective gel.
Data are expressed as means  SE.
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compared with baseline, Table 1). Hexamethonium did not
affect HR (control, 3  6; INS, 9  2; control-LOS 1 
5; and INSLOS , 10  3% of baseline, Table 1). Air-jet
stress caused no significant differences in absolute BP changes.
However, the INS group showed a tendency toward lower
MAP response compared with control, (MAP: control, 32 
3; INS, 19  4; control-LOS, 36  7; INSLOS , 29 
7% of baseline). HR response to air-jet stress was similar in all
groups (HR: control, 7  8; INS, 7  8; control-LOS,
6  6; INSLOS 5  11% of baseline, Table 1).
Losartan improves ACh-induced vasodilation in hyperinsu-
linemic rat aortae. Insulin did not affect ACh-dependent vaso-
dilation significantly (control, 90 5 vs. INS, 81 4%, Fig. 2A).
However, losartan significantly improved NO-mediated vasodila-
tion in insulin-treated rats (INS, 81 4 vs. INSLOS, 97 2%,
P  0.01, Fig. 2C). We observed no difference in SNP-induced
vasodilation (95% in all groups). In addition, normalized inter-
nal diameter, potassium response, NE response, or ACh-mediated
vasodilation did not differ in the mesenteric arteries (data not
shown).
PRC increased after 2 wk of insulin treatment. While insulin
treatment increased PRC significantly in the INS group at 2 wk
(control, 37  3 vs. INS, 76  13*102 mGU/ml, P  0.05),
we observed no significant difference after 6 wk (control, 51
7 vs. INS, 68  15*102 mGU/ml). Losartan treatment in-
creased PRC in both groups at 2 and 6 wk (2 wk: control-LOS,
1,402  160 and INSLOS , 1,567  143*102 mGU/ml,
P  0.001, 6 wk: control-LOS, 807  181 and INSLOS ,
2,005  385*102 mGU/ml, P  0.001). Whereas PRC
remained more or less constant in all groups between weeks 2
and 6, PRC decreased significantly in the control-LOS group
during the same time period (P  0.05).
Gene and protein expression. We observed no difference in
mRNA expression of the 
1a-receptor in the mesenteric
arteries (control, 3.4  1.0; control-LOS, 2.5  0.4; INS,
5.2  1.2; and INSLOS , 3.0  0.8 arbitrary units).
Western blot analysis of mesenteric adipose tissue showed
no differences in AT1 receptor expression (Fig. 3A) or ACE
expression (Fig. 3B).
Study 2
Similar MAP, increased HR in hyperinsulinemic rats. MAP
did not differ in INS and control animals in the second study
(repeated-measurements ANOVA; time, P  0.018; group,
P  0.552; time*group, P  0.987). However, HR increased
significantly 3 days after commencing insulin treatment, and
this difference remained throughout the study (repeated-mea-
surements ANOVA; time, P  0.0001; group, P  0.016;
time*group, P  0.0001, Fig. 4).
No differences in acute effects of losartan. To study whether
hyperinsulinemic rats develop sensitization to RAAS, we admin-
istered a single dose of losartan 2, 4, and 6 wk after initiating
insulin treatment. Acute dosing showed a similar MAP response
in the control and INS groups at 2, 4, and 6 wk of insulin treatment
(2 wk: control, 13  2 vs. INS, 16  3% of baseline; 4 wk:
control,12 3 vs. INS,19 3% of baseline; 6 wk: control,
10  3 vs. INS, 17  2% of baseline, Table 2). HR did not
change significantly following losartan treatment (2 wk: control,
12  3 vs. INS, 5  4% of baseline; 4 wk: control, 17 
3 vs. INS,4 5% of baseline; 6 wk: control,1 6 vs. INS,
97  4% of baseline, Table 2).
BP and HR respond similarly to ganglionic blockade. Study
2 used pentolinium to block ganglionic traffic. Compared with
hexamethonium (study 1), pentolinium has a slightly different
pharmacological profile, and the effect of pentolinium lasted
Fig. 4. MAP (A) and HR (B) before (1), at start (0), and after 2, 4, and 6 wk
of hyperinsulinemia (n  8/group). Data are expressed as means  SE.
Repeated-measurements ANOVA for HR; time, P  0.0001, group, P 
0.016, time*group, P  0.0001.
Table 2. Effects of angiotensin II receptor antagonist losartan (30 mg/kg) on MAP and HR after 2, 4, and 6 wk of insulin
treatment in study 2
Group n
Week 2 MAP/HR Week 4 MAP/HR Week 6 MAP/HR
Baseline Post Baseline Post Baseline Post
Control 8 1073/37913 932/42412 1093/36311 954/42416 1063/38318 952/38210
Insulin 8 1103/42215 924/44010 1112/40711 914/4187 1053/42219 872/40816
Values are means  SE; n  number of rats per group.
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longer. Pentolinium did not affect MAP or HR response (MAP
week 2: control, 14  6; INS, 14  8% of baseline; week
4: control, 30  2; INS, 35  3% of baseline; week 6:
control, 27  2; INS, 24  7% of baseline, Table 3).
Blunted MAP response during air-jet stress? MAP response
to air-jet stress did not change after 2 wk of insulin treatment
(control, 30  2 vs. INS, 24  3% of baseline, Table 3).
Although MAP response in the insulin-treated animals de-
creased significantly during week 4 (control, 36  3 vs. INS,
28  2%, P  0.05, Table 3), we observed no difference
during week 6 (control, 30  vs. INS, 27  2%, Table 3).
To increase the statistical power of our analyses, we pooled
data from week 5 of study 1 and week 6 of study 2. Subsequent
analysis of the pooled data showed a significantly smaller
increase in BP in response to air-jet stress in the INS group
(control, 30  2 vs. INS, 23  2, P  0.03).
Rats are hyperinsulinemic and euglycemic. Since none of the
following parameters differed significantly between the control
and INS groups in studies 1 and 2, we combined them (Table 4).
Hyperinsulinemic INS and INSLOS rats had normal blood
glucose levels (Table 4). Body weight increased in INS rats
compared with control animals (P  0.001, Table 4).
INSLOS treatment prevented an insulin-mediated increase in
body weight (P  0.001, Table 4). Losartan did not influence
body weight in control animals (Table 4).
Left ventricular weight. Hyperinsulinemia resulted in in-
creased left ventricular weight (LVW; P  0.01 vs. C, Table
4), and losartan reduced LVW (P  0.001). However, after
normalizing LVW to body weight, we observed no differences
between control and INS. Losartan treatment reduced LVW
significantly in the control animals (P  0.001, Table 4), a
difference that persisted after normalization for body weight
(P  0.001 for both, Table 4).
DISCUSSION
We show here that chronic insulin treatment in rats sensi-
tizes BP control to RAAS. Hyperinsulinemia per se does not
affect BP, but chronic treatment with the angiotensin receptor
blocker losartan lowers BP nearly 40 mmHg, suggesting that
an intact RAAS participates importantly in BP control. How-
ever, we found no convincing evidence of increased baseline
sympathetic activity in hyperinsulinemic rats and no increased
vascular reactivity to stressful stimuli.
Insulin Infusion Does Not Affect BP Chronically in
Unrestrained Rats
The literature is widely inconsistent regarding the effects of
hyperinsulinemia on BP. Some studies show increased BP (5,
8, 26, 35), while others show no effect (12, 22) or even acutely
reduced BP (1, 34). Some of these apparent inconsistencies
most likely depend on the level of hyperinsulinemia achieved
and resultant glucose levels, the length of the observation
period, and differences between species. The current study was
designed to look at both the immediate and more long-term
effects of insulin on BP. We used a model in which glucose is
supplemented orally, achieving normal plasma glucose at 2 wk.
Despite oral supplementation, glucose kinetics are altered, evi-
denced by an increased insulin sensitivity (13, 14). Our study,
which used telemetry and allowed freely moving unrestrained BP
measurements in home cages, shows that insulin does not affect
BP in rats rendered hyperinsulinemic for 6 wk. The data is in
disagreement with a previous study using telemetry and infusing
insulin for 10 days (26). In the study by Meehan et al. (26) oral
glucose was administered to both control and insulin group, and
the achieved plasma insulin was comparable to the current study
(8 and 12 times increase, respectively). The administration of
glucose to the control groups makes it hard to compare the two
studies since glucose per se resulted in a marked increase in
systolic BP. The data is also in disagreement with the study by
Fang and Huang (7) who reported increased BP after insulin in a
42-days-long study. However, in this study BP was measured
using tail cuff technique, and glucose was not supplemented in
drinking water. We believe that our data are solid since we have
used state-of-the-art BP technique and reproduced identical find-
ings in two separate studies. It is interesting to note that all
previous studies reporting an increase in BP after insulin is
performed in male rats (8, 26, 35). This would suggest a possible
sex difference in the susceptibility toward insulin. Another pos-
sibility is that the data by Fang and Huang (7) might result from
interactions between insulin’s sympathofacilitation and the stress-
ful stimuli of tail cuff BP measurement.
No Differences in Sympathetic Activity or Reactivity
Therefore, we sought to assess in hyperinsulinemic rats the
degree of baseline sympathetic activity as well as sympathetic
reactivity. Earlier reports suggested that hyperinsulinemia con-
tributes to hypertension by a sympathostimulatory effect in
humans (28) and animals (38). In the current study, HR
consistently increased after insulin treatment and also through-
out the study, possibly indicating altered autonomic tone.
However, ganglion blockade reduced BP and HR similarly in
all groups and at all time points in both studies. Furthermore,
mesenteric resistance vessels showed similar mRNA expression
of the 
1a-receptor. These findings do not support increased
resting sympathetic tone in hyperinsulinemic rats as an explana-
tion to the increased HR. However, ganglion blockade does not
test for sympathetic reactivity. Indeed, a recent report suggested
that rats rendered hyperinsulinemic by fructose feeding develop
Table 3. Effects of ganglion antagonist pentolinium (10 mg/kg) and air-jet stress on mean arterial pressure (MAP)
and heart rate (HR) after 2, 4, and 6 weeks of insulin treatment in study 2
Group n
Week 2 MAP/HR Week 4 MAP/HR
Pentolinium Air-jet Stress Pentolinium
Baseline Post Baseline Stress Post Stress Baseline Post
Control 8 1003/39313 867/41313 1012/3706 1312/43614 1202/43212 981/3547 756/38914
Insulin 8 1002/3909 868/39610 1053/39213 1302/4438 1182/43415 952/38915 623/39216
Values are means  SE; n  number of rats per group.
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stress-sensitive hypertension (6). Therefore, we submitted our
hyperinsulinemic rats to air-jet stress. Such stress did not augment
MAP or HR response; on the contrary, hyperinsulinemic rats
showed blunted stress response compared with control rats. This
finding was not totally consistent and will require further study.
However, we show here that hyperinsulinemic rats are neither
hyperreactive nor more stress sensitive during air-jet stress. The
explanation to the observed increase in HR could be vagal
withdrawal or regional alterations in sympathetic tone.
Chronic Interaction of Angiotensin II and Insulin
Interestingly, chronic treatment of hyperinsulinemic rats
with the AT1 receptor antagonist losartan resulted in markedly
reduced BP (40 mmHg) compared with a more modest reduc-
tion in the losartan-treated control group with (18 mmHg),
suggesting that RAAS may contribute importantly to BP con-
trol in hyperinsulinemia. Since administration of angiotensin II
during hyperinsulinemia results in greater BP response, others
have suggested that insulin increases angiotensin II sensitivity
(30). Increased RAAS sensitivity might result from differences
in receptor quantity or increased RAAS activity. Although we
observed transiently increased PRC after 2 wk of insulin
treatment, thus corroborating earlier reports (15, 19, 20) and
also on renin release in diabetic animals (18), such action does
not explain satisfactorily the effect of chronic losartan treatment.
Earlier reports suggest that angiotensin II can impair
insulin-induced phosphorylation of endothelial NO syn-
thase, thereby reducing NO availability (36). This is sup-
ported by our data showing that losartan treatment signifi-
cantly enhances ACh-induced vasodilatation in the aorta of
insulin-treated rats. However, since we found no similar
changes in the mesenteric resistance vessels, this finding
likely does not affect BP control. Small vessel myograph
revealed no differences in contractile response to potassium,
suggesting that no functionally important vascular remod-
eling occurs in resistance vessels; thus, the increased RAAS
dependency is not due to vascular changes induced by
trophic actions of insulin. Local RAAS in adipose tissue
(21) likely contributes to angiotensin II production. Insulin
increased adipose tissue (2) and thus increased locally-
derived angiotensin II and RAAS dependency. Therefore,
we performed immunoblotting against the AT1 receptor and
ACE in mesenteric adipose tissue. We observed no differ-
ences in the expression of these RAAS components.
Our data shows that single-dose losartan does not increase
RAAS dependency during acute antagonism of the angiotensin II
receptor. Furthermore, BP reduction following acute losartan
treatment was less than the chronic effect of losartan in hyperin-
sulinemic rats, suggesting that cross talk between angiotensin II
and hyperinsulinemia, revealed in our chronic treatment pro-
tocol, results from long-term changes in insulin/angiotensin
signaling not affected by acute receptor antagonism.
Losartan Reverses LVW
LVW increased following insulin treatment and decreased
following losartan treatment. Moreover, losartan decreased
LVW in control animals in relation to achieved BP reduction
(17% BP reduction, 17% reduction in LVW). However, de-
creased LVW in the INSLOS group was less than expected
in relation to achieved BP (39% BP reduction compared with
25% reduction in LVW), suggesting that insulin per se acts as
a cardiac growth factor. However, such data requires cautious
interpretation since insulin affects body weight, fat mass, and
tibia length (37), making it harder to normalize LVW between
groups. Using body weight as normalization factor dimin-
ishes differences in LVW. In a parallel study (Johansson
ME, Alexanderson C, Holma¨ng A, Bergstro¨m G, unpublished
data), we estimated lean body mass using dual-energy X-ray
absorptiometry. This normalization procedure also diminished
LVW differences between the insulin-treated and control group.
Perspectives and Significance
The worldwide epidemic of diabetes has stimulated research on
the hemodynamic importance of insulin. Our results raise doubt
regarding the role of insulin per se in hypertension, and, further-
Table 3.—Continued
Week 4 MAP/HR Week 6 MAP/HR
Air-jet Stress Pentolinium Air-jet Stress
Baseline Stress Post Stress Baseline Post Baseline Stress Post Stress
983/3394 1332/42313 1162/41110 1002/3404 732/39613 1012/34910 1312/44912 1182/41912
1012/36910 1294/45314 1145/44816 1003/38115 756/39012 1022/3648 1292/44810 1142/43616
Table 4. Effect of chronic insulin and/or angiotensin receptor antagonist (losartan) treatment on body weight (BW), insulin,
and glucose levels, left and right ventricle weight (LVW, RVW) normalized to body weight (LVW/BW, RVW/BW)
Group n BW, g
Insulin,
mU/ml
Glucose,
mmol/l LVW, g
LVW/BW,
g/kg RVW, g RVW/BW, g/kg
Control 21 3035 333 7.70.2 0.7140.013 2.360.03 0.1930.004 0.6400.013
Control losartan 10 2956 375 8.90.3 0.5930.021a 2.010.05 0.1600.011c 0.5410.031c
Insulin 21 3506a 395103e 6.90.3 0.7880.018e 2.250.04 0.2150.007 0.6190.024
Insulin-losartan 11 3047b 429170c 7.10.9 0.5900.012b 1.940.04 0.1780.012d 0.5810.035
Values are means  SE; n  number of rats per group. aP  0.001 vs. control, bP  0.001 vs. insulin, cP  0.05 vs. control, dP  0.01 vs. insulin, eP 
0.01 vs. control.
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more, we found no evidence for insulin to activate SNS or to
increase cardiovascular reactivity toward stressful stimuli. Impor-
tantly, however, we show that insulin combined with an angio-
tensin receptor blocker results in marked reductions in BP. These
results point to an important interaction between insulin and
angiotensin II that could be of importance in understanding the
beneficial effects of angiotensin receptor blockers in diabetics.
ACKNOWLEDGMENTS
The authors express sincere gratitude to Gunnel Andersson, Jia Jing,
Britt-Mari Larsson, Inge Andersen, and Mette Fredenslund for excellent
technical assistance.
GRANTS
This study was supported by the Swedish Medical Research Council, the
Swedish Heart Lung foundation, The Swedish Diabetes Association Research
Foundation, funds at the Sahlgrenska University hospital (LUA/ALF), and the
Lundberg foundation.
REFERENCES
1. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle
blood flow. A possible link between insulin resistance and blood pressure.
Hypertension 21: 129–135, 1993.
2. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesity-
associated activation of angiotensin and endothelin in the cardiovascular
system. Int J Biochem Cell Biol 35: 826–837, 2003.
3. Bergstrom G, Nystrom HC, Jia J, Evans RG. Effects of the ETA/ETB
antagonist, TAK-044, on blood pressure and renal excretory function after
unclipping of conscious one-kidney-one-clip hypertensive rats. J Hyper-
tens 19: 659–665, 2001.
4. Bohlooly YM, Carlson L, Olsson B, Gustafsson H, Andersson IJ,
Tornell J, Bergstrom G. Vascular function and blood pressure in GH
transgenic mice. Endocrinology 142: 3317–3323, 2001.
5. Brands MW, Harrison DL, Keen HL, Gardner A, Shek EW, Hall JE.
Insulin-induced hypertension in rats depends on an intact renin-angioten-
sin system. Hypertension 29: 1014–1019, 1997.
6. D’Angelo G, Elmarakby AA, Pollock DM, Stepp DW. Fructose feeding
increases insulin resistance but not blood pressure in Sprague-Dawley rats.
Hypertension 46: 806–811, 2005.
7. Fang TC, Huang WC. Angiotensin receptor blockade blunts hyperinsu-
linemia-induced hypertension in rats. Hypertension 32: 235–242, 1998.
8. Fang TC, Huang WC. Role of angiotensin II in hyperinsulinemia-
induced hypertension in rats. J Hypertens 16: 1767–1774, 1998.
9. Grassi G, Seravalle G, Dell’Oro R, Trevano FQ, Bombelli M, Scop-
elliti F, Facchini A, Mancia G. Comparative effects of candesartan and
hydrochlorothiazide on blood pressure, insulin sensitivity, and sympa-
thetic drive in obese hypertensive individuals: results of the CROSS study.
J Hypertens 21: 1761–1769, 2003.
10. Hagg U, Andersson I, Naylor AS, Gronros J, Jonsdottir IH, Berg-
strom G, Gan LM. Voluntary physical exercise-induced vascular effects
in spontaneously hypertensive rats. Clin Sci (Lond) 107: 571–581, 2004.
11. Hagg U, Johansson ME, Gronros J, Naylor AS, Jonsdottir IH, Bergstrom
G, Svensson PA, Gan LM. Gene expression profile and aortic vessel
distensibility in voluntarily exercised spontaneously hypertensive rats: poten-
tial role of heat shock proteins. Physiol Genomics 22: 319–326, 2005.
12. Hall JE, Brands MW, Mizelle HL, Gaillard CA, Hildebrandt DA.
Chronic intrarenal hyperinsulinemia does not cause hypertension. Am J
Physiol Renal Fluid Electrolyte Physiol 260: F663–F669, 1991.
13. Holmang A, Brzezinska Z, Bjorntorp P. Effects of hyperinsulinemia on muscle
fiber composition and capitalization in rats. Diabetes 42: 1073–1081, 1993.
14. Holmang A, Jennische E, Bjorntorp P. The effects of long-term hyperin-
sulinaemia on insulin sensitivity in rats. Acta Physiol Scand 153: 67–73, 1995.
15. Iyer SN, Raizada MK, Katovich MJ. AT1 receptor density changes
during development of hypertension in hyperinsulinemic rats. Clin Exp
Hypertens 18: 793–810, 1996.
16. Johansson ME, Hagg U, Wikstrom J, Wickman A, Bergstrom G, Gan
LM. Haemodynamically significant plaque formation and regional endo-
thelial dysfunction in cholesterol-fed ApoE(/) mice. Clin Sci (Lond)
108: 531–538, 2005.
17. Johansson ME, Wickman A, Fitzgerald SM, Gan LM, Bergstrom G.
Angiotensin II, type 2 receptor is not involved in the angiotensin II-
mediated pro-atherogenic process in ApoE/ mice. J Hypertens 23:
1541–1549, 2005.
18. Jost-Vu E, Horton R, Antonipillai I. Altered regulation of renin secre-
tion by insulinlike growth factors and angiotensin II in diabetic rats.
Diabetes 41: 1100–1105, 1992.
19. Kamide K, Hori MT, Zhu JH, Barrett JD, Eggena P, Tuck ML.
Insulin-mediated growth in aortic smooth muscle and the vascular renin-
angiotensin system. Hypertension 32: 482–487, 1998.
20. Kamide K, Rakugi H, Higaki J, Okamura A, Nagai M, Moriguchi K,
Ohishi M, Satoh N, Tuck ML, Ogihara T. The renin-angiotensin and
adrenergic nervous system in cardiac hypertrophy in fructose-fed rats.
Am J Hypertens 15: 66–71, 2002.
21. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin
Endocrinol Metab 89: 2548–2556, 2004.
22. Koopmans SJ, Ohman L, Haywood JR, Mandarino LJ, DeFronzo RA.
Seven days of euglycemic hyperinsulinemia induces insulin resistance for
glucose metabolism but not hypertension, elevated catecholamine levels, or
increased sodium retention in conscious normal rats. Diabetes 46: 1572–1578,
1997.
23. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K,
Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S,
Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS,
Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S. Risk
of new-onset diabetes in the Losartan Intervention For Endpoint Reduction
in Hypertension Study. J Hypertens 20: 1879–1886, 2002.
24. Lykkegard S, Poulsen K. Ultramicroassay for plasma renin concentration
in the rat using the antibody-trapping technique. Anal Biochem 75:
250–259, 1976.
25. McDougall SJ, Lawrence AJ, Widdop RE. Differential cardiovascular
responses to stressors in hypertensive and normotensive rats. Exp Physiol
90: 141–150, 2005.
26. Meehan WP, Buchanan TA, Hsueh W. Chronic insulin administration
elevates blood pressure in rats. Hypertension 23: 1012–1017, 1994.
27. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L,
Enerback S. Increased expression of the transcription factors CCAAT-
enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate
with invasiveness of human colorectal cancer. Int J Cancer 86: 337–343,
2000.
28. Reaven GM, Lithell H, Landsberg L. Hypertension and associated
metabolic abnormalities–the role of insulin resistance and the sympathoa-
drenal system. N Engl J Med 334: 374–381, 1996.
29. Reid IA. Interactions between ANG II, sympathetic nervous system, and
baroreceptor reflexes in regulation of blood pressure. Am J Physiol
Endocrinol Metab 262: E763–E778, 1992.
30. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL.
Hyperinsulinemia and the aldosterone and pressor responses to angioten-
sin II. Hypertension 15: 861–866, 1990.
31. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg
L. Effect of insulin and glucose infusions on sympathetic nervous system
activity in normal man. Diabetes 30: 219–225, 1981.
32. Samuelsson AM, Bollano E, Mobini R, Larsson BM, Omerovic E, Fu
M, Waagstein F, Holmang A. Hyperinsulinemia: effect on cardiac
mass/function, angiotensin II receptor expression, and insulin signaling
pathways. Am J Physiol Heart Circ Physiol 291: H787–H796, 2006.
33. Shao R, Markstrom E, Friberg PA, Johansson M, Billig H. Expression
of progesterone receptor (PR) A and B isoforms in mouse granulosa cells:
stage-dependent PR-mediated regulation of apoptosis and cell prolifera-
tion. Biol Reprod 68: 914–921, 2003.
34. Spraul M, Ravussin E, Baron AD. Lack of relationship between muscle
sympathetic nerve activity and skeletal muscle vasodilation in response to
insulin infusion. Diabetologia 39: 91–96, 1996.
35. Tomiyama H, Kushiro T, Abeta H, Kurumatani H, Taguchi H, Kuga
N, Saito F, Kobayashi F, Otsuka Y, Kanmatsuse K, Kajiwara N. Blood
pressure response to hyperinsulinemia in salt-sensitive and salt-resistant
rats. Hypertension 20: 596–600, 1992.
36. Velloso LA, Folli F, Perego L, Saad MJ. The multi-faceted cross-talk
between the insulin and angiotensin II signaling systems. Diabetes Metab
Res Rev 22: 98–107, 2006.
37. Verhaeghe J, Suiker AM, Visser WJ, Van Herck E, Van Bree R,
Bouillon R. The effects of systemic insulin, insulin-like growth factor-I
and growth hormone on bone growth and turnover in spontaneously
diabetic BB rats. J Endocrinol 134: 485–492, 1992.
38. Young JB. Effect of experimental hyperinsulinemia on sympathetic ner-
vous system activity in the rat. Life Sci 43: 193–200, 1988.
R1247HYPERINSULINEMIA AND ANGIOTENSIN II
AJP-Regul Integr Comp Physiol • VOL 294 • APRIL 2008 • www.ajpregu.org
 by 10.220.33.4 on January 9, 2017
http://ajpregu.physiology.org/
D
ow
nloaded from
 
